First Script saw continued decreasing opioid trends across our retail and mail-order programs in 2019, even while overall prescription trends saw a slight upward shift in utilization per claim and cost per claim. Even with these changes, opioids remain the #1 therapeutic class by usage and cost, however, 2019 marked the largest reduction of the last 5 years in the percentage of opioid scripts with greater than or equal to 90 MED. View the video blog here.
SAN DIEGO—October 19, 2021—Enlyte, the new parent brand unifying Mitchell, Genex and Coventry, today released its inaugural report
SAN DIEGO, CA—October 13, 2021—Mitchell, Genex and Coventry formally announced today the creation of their new parent brand, Enlyt
As a unified brand, Enlyte aligns the companies’ teams to enable improved client focus, while leveraging the breadth of solutions and expertis
The Mitchell | Genex | Coventry team looks forward to connecting with you at the 2021 mPower Conference, taking place virtually October 12–14, 2021
Disability Case Management Meet Nancy LeBlanc, RN, CCM, CPDM, WES
By Richard Leonardo, Senior VP of IME and Specialty Services, Genex Services